Vobarilizumab

N/A

Report date: 2023/08/01 20:00:44

Base Information

Drug NameVobarilizumab
Drug Alias NameANTI-IL-6R20A11-9mer-ALB11Anti-IL-6R NanobodyALX-0061
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionInterleukin-6 receptor alpha subunit antagonistsInterleukin-6 receptor subunit beta antagonists
TargetsInterleukin-6 receptor alpha subunitInterleukin-6 receptor subunit beta
Therapy Area/IndicationsLupus Erythematosus, SystemicArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[24] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAblynx Nv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbvie IncAblynx Nv
Active IndicationsN/A
Inactive IndicationsLupus Erythematosus, SystemicArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksWikipedia